National Institutes of Health

Rhealth is a biotechnology company that focuses on delivering advanced health management solutions through an AI-driven platform tailored for hospitals. It aims to enhance the accessibility of analytical and diagnostic information for both physicians and patients. By integrating portable diagnostic and monitoring technologies, Rhealth seeks to transform the way health information is accessed and utilized, ultimately enabling healthcare providers to deliver more timely and effective care.

Amissa develops mobile and wearable application solutions aimed at alleviating the challenges of Alzheimer's care. The company’s technology empowers caregivers by allowing them to geo-fence and locate loved ones who may wander, remotely monitor their activity and health, and predict behaviors associated with Alzheimer's. In addition to these features, Amissa offers wearable biosensors integrated with a cloud-based data platform that collects biometric data on activity levels, sleep patterns, and physiological changes. This comprehensive approach not only aids caregivers in monitoring patients but also provides valuable insights for researchers seeking to understand disease progression, ultimately enhancing the quality of life for individuals with dementia and related disorders.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

MaMome is dedicated to advancing women's health, beginning with pregnancy, and extending beyond, by utilizing microbiome coupled with machine learning/AI, we precisely identify expectant mothers at elevated risk of pregnancy complications.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company focuses on preclinical and toxicology services, utilizing proprietary orthotopic and metastatic tumor models. L2P Research Labs offers a range of advanced technologies, including quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans, as well as focal radiation. These capabilities allow researchers to access a complete suite of research services tailored to their needs, facilitating the advancement of scientific studies and drug development.

NeuroGeneces utilizes advanced neuroscience, sleep expertise, and artificial intelligence to deliver brain health assessments aimed at enhancing cognitive longevity. The company has received funding from various reputable sources, including government agencies and private investors. Its flagship product is a sleep headband equipped with machine learning algorithms that analyze EEG data, comparing it against a proprietary normative database to determine an individual's biological brain age. This innovative approach allows healthcare practitioners to objectively evaluate brain function and develop targeted intervention strategies. Additionally, the device monitors sleep patterns, including quantity, quality, and heart rate variability, providing essential support for clinicians focused on wellness and preventative care. By identifying neurodegeneration early, NeuroGeneces aims to empower users to optimize their mental and physical performance.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

Applied BioMath, LLC offers systems biology and pharmacology services to biotechnology and pharmaceutical companies, focusing on accelerating and de-risking drug research and development. Founded in 2013, the company specializes in developing pathway models, conducting feasibility assessments for drug targets, and performing dose projections, among other services. Their advanced mathematical modeling and simulation platform enables clients to employ quantitative decision-making strategies, improving their understanding of drug discovery processes. Additionally, Applied BioMath provides systems informatics services, including principal components analysis and Boolean logic analysis. The company has established strategic alliances with organizations such as Sanofi and Xilio Therapeutics, enhancing its capabilities and market presence. Based in Concord, Massachusetts, with additional offices in Cambridge and Oakland, Applied BioMath aims to reduce late-stage attrition in drug development through its innovative approaches and expertise.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

Aural Analytics, Inc. is a Scottsdale, Arizona-based company founded in 2015 that focuses on developing applications for monitoring brain health. The company has created a multi-modal brain health analytics platform that utilizes advances in artificial intelligence, neuroscience, and speech analytics to detect changes in neurological health. By leveraging proprietary metrics, Aural Analytics transforms smartphones and tablets into effective brain health monitors, capturing subtle, clinically relevant aspects of a patient's condition through speech samples. This technology enhances traditional functional rating scales used in clinical trials by providing objective, continuous outcomes, thereby allowing for more reliable evaluations of drug efficacy and other interventions. Aural Analytics' platform aims to reveal incremental changes in neurological health, facilitating accurate assessments by medical professionals.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

Datirium offers a scientific data analysis web platform known as SciDAP, designed to facilitate the integration and analysis of Next Generation Sequencing (NGS) data for biologists. The platform aims to enhance collaboration between biologists and bioinformaticians by providing user-friendly, push-button analysis tools alongside options for advanced customization. SciDAP presents analytical data in a visually accessible format, enabling biologists to quickly comprehend complex concepts and identify new patterns. It also allows users to delve deeper into the data through interactive charts and graphs, promoting a more thorough understanding. By enabling biologists to perform analyses independently and automate routine tasks, Datirium's platform bridges the gap between scientific research and data management.

Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.

Dascena, Inc. is a healthcare technology company based in Oakland, California, that specializes in developing machine learning algorithms aimed at enhancing patient care and early disease intervention. Founded in 2018, Dascena focuses on creating algorithmic software that processes electronic health record data to predict critical conditions such as acute decompensation, sepsis, and acute kidney injury. By leveraging extensive clinical research, the company provides tools that support clinical decision-making, facilitate point-of-care diagnostics, and serve as biopharma companion diagnostics. Dascena's innovations address significant unmet healthcare needs, ultimately aiming to improve care outcomes and save lives through timely and accurate interventions.

Datirium offers a scientific data analysis web platform known as SciDAP, designed to facilitate the integration and analysis of Next Generation Sequencing (NGS) data for biologists. The platform aims to enhance collaboration between biologists and bioinformaticians by providing user-friendly, push-button analysis tools alongside options for advanced customization. SciDAP presents analytical data in a visually accessible format, enabling biologists to quickly comprehend complex concepts and identify new patterns. It also allows users to delve deeper into the data through interactive charts and graphs, promoting a more thorough understanding. By enabling biologists to perform analyses independently and automate routine tasks, Datirium's platform bridges the gap between scientific research and data management.

Arcascope develops health and fitness applications that focus on optimizing the body's internal circadian rhythms. By utilizing algorithms that analyze data from smartphones and wearable devices, the company tracks users' circadian clocks in real-time. This information allows Arcascope to generate personalized recommendations aimed at helping individuals adjust their sleep patterns and improve overall well-being. Through its innovative approach, Arcascope enables users to mitigate fatigue and enhance their daily life by effectively aligning their biological clocks.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Datirium offers a scientific data analysis web platform known as SciDAP, designed to facilitate the integration and analysis of Next Generation Sequencing (NGS) data for biologists. The platform aims to enhance collaboration between biologists and bioinformaticians by providing user-friendly, push-button analysis tools alongside options for advanced customization. SciDAP presents analytical data in a visually accessible format, enabling biologists to quickly comprehend complex concepts and identify new patterns. It also allows users to delve deeper into the data through interactive charts and graphs, promoting a more thorough understanding. By enabling biologists to perform analyses independently and automate routine tasks, Datirium's platform bridges the gap between scientific research and data management.

DiamiR is mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care.

Arcascope develops health and fitness applications that focus on optimizing the body's internal circadian rhythms. By utilizing algorithms that analyze data from smartphones and wearable devices, the company tracks users' circadian clocks in real-time. This information allows Arcascope to generate personalized recommendations aimed at helping individuals adjust their sleep patterns and improve overall well-being. Through its innovative approach, Arcascope enables users to mitigate fatigue and enhance their daily life by effectively aligning their biological clocks.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

DrugPredict is developed by the cooperation of Delta Informatika Inc., a Hungarian informatics company and three universities: Eötvös Loránd University, Semmelweis University and University of Debrecen.

HealthRhythms develops a mental health assessment and treatment platform that focuses on measuring and monitoring health conditions. Utilizing advanced machine learning and predictive analytics, the company offers innovative health assessments and personalized interventions aimed at enhancing the care delivery experience for patients, health plans, payers, and research organizations. Its platform enables continuous, objective monitoring of behavioral health, allowing for real-time tracking of mental health status. By anticipating clinical deterioration, HealthRhythms delivers tailored interventions based on individual patient profiles, assisting healthcare providers in effectively identifying, managing, and characterizing patients' mental health needs.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute focused on utilizing genomic and clinical data to advance personalized healthcare. As part of the Inova Center for Personalized Health, ITMI fosters collaboration among researchers, clinicians, and consumers to integrate genomic research into patient care, prevention, and wellness strategies. This innovative approach aims to shift healthcare from a reactive model to a predictive one, enhancing longevity and improving health outcomes. ITMI conducts research that generates extensive genomic and clinical datasets, which are valuable for various fields, including computational biology, psychology, and biomedical research. By analyzing genomic information, ITMI seeks to understand disease onset and promote preventative medicine, thereby enhancing treatment efficacy and minimizing adverse reactions.

ReThink Medical, Inc. is a medical device and digital health company based in San Francisco, California, specializing in the development of a wrist-worn monitoring device. Founded in 2010 and now a subsidiary of Terumo Corporation, ReThink Medical focuses on predicting and preventing heart failure hospitalizations through continuous physiological monitoring and advanced machine learning algorithms. Its flagship product, CorBand™, is designed to detect and notify users of worsening heart conditions weeks in advance, even before noticeable symptoms emerge. This proactive approach emphasizes compliance, simplicity, and accuracy, aiming to improve quality of life for patients while significantly reducing healthcare costs. The device monitors key indicators such as heartbeat rate and fluid status, enabling timely intervention and management of heart-related disorders.

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

ReThink Medical, Inc. is a medical device and digital health company based in San Francisco, California, specializing in the development of a wrist-worn monitoring device. Founded in 2010 and now a subsidiary of Terumo Corporation, ReThink Medical focuses on predicting and preventing heart failure hospitalizations through continuous physiological monitoring and advanced machine learning algorithms. Its flagship product, CorBand™, is designed to detect and notify users of worsening heart conditions weeks in advance, even before noticeable symptoms emerge. This proactive approach emphasizes compliance, simplicity, and accuracy, aiming to improve quality of life for patients while significantly reducing healthcare costs. The device monitors key indicators such as heartbeat rate and fluid status, enabling timely intervention and management of heart-related disorders.

Noom, Inc. is a New York-based company that specializes in mobile health coaching through a psychology-based digital health platform. Founded in 2008, Noom develops a mobile application that combines evidence-based curricula, personalized coaching, and data-driven insights to help users achieve their health and wellness goals, including weight management and chronic disease prevention. The platform offers scalable tools for exercise and nutrition coaching, utilizing artificial intelligence to facilitate behavioral change. Recognized for its innovative approach, Noom has received multiple grants from the National Institutes of Health and was the first mobile application certified by the Centers for Disease Control as a diabetes prevention program. The company also caters to business enterprises, supporting organizations in promoting employee health. With additional offices in Seoul and Tokyo, Noom continues to expand its global reach and impact on personal health management.